Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib Peri-Transplant in Myelofibrosis
NCT02917096Phase 1Completed
- Sponsor
- City of Hope
- Start
- Nov 2016
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in myelofibrosis (MF), sponsored by City of Hope. Primary endpoint: Maximum Tolerated Dose at 45 days. Started Nov 2016; status: completed.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT02917096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02917096.